Janus Henderson Group PLC Increases Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

Janus Henderson Group PLC grew its position in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 34.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,760,074 shares of the company's stock after acquiring an additional 2,232,507 shares during the quarter. Janus Henderson Group PLC owned 8.79% of Zai Lab worth $211,488,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZLAB. Bamco Inc. NY raised its stake in shares of Zai Lab by 6.4% during the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company's stock worth $46,023,000 after purchasing an additional 113,869 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Zai Lab by 26.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company's stock worth $14,584,000 after purchasing an additional 125,532 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of Zai Lab by 1.4% during the 2nd quarter. TD Asset Management Inc now owns 221,970 shares of the company's stock worth $3,847,000 after purchasing an additional 3,000 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Zai Lab by 14.6% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 142,189 shares of the company's stock worth $3,432,000 after purchasing an additional 18,093 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Zai Lab by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 121,084 shares of the company's stock worth $2,923,000 after purchasing an additional 3,860 shares in the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZLAB. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. increased their target price on Zai Lab from $38.00 to $44.00 and gave the company an "overweight" rating in a research report on Monday, October 21st.

Zai Lab Trading Down 6.1 %

ZLAB stock traded down $1.85 during mid-day trading on Wednesday, reaching $28.31. The company's stock had a trading volume of 903,714 shares, compared to its average volume of 720,289. The company has a market cap of $3.08 billion, a price-to-earnings ratio of -10.22 and a beta of 0.99. The business's 50 day moving average price is $27.80 and its 200 day moving average price is $21.90. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $36.60.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.